Erasca (ERAS) Non-Current Assets (2020 - 2026)
Erasca (ERAS) reported Non-Current Assets of $207.4 million for Q1 2026, up 32.45% on a YoY basis from $156.6 million in Q1 2025, and up 88.74% quarter-over-quarter from $109.9 million in Q4 2025.
Erasca (ERAS) Non-Current Assets (2020 - 2026) Analysis & Trends
Erasca has reported Non-Current Assets for 7 years, with the latest figure at $207.4 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 32.45% year-over-year to $207.4 million; the trailing twelve-month figure through Mar 2026 stood at $572.6 million (down 12.83% YoY), and the FY2025 full-year result was $109.9 million, down 43.26% from the prior year.
- Non-Current Assets for Q1 2026 stood at $207.4 million, up from $109.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $207.4 million in Q1 2026, with the low at $63.4 million in Q1 2024.
- Historically, Non-Current Assets has averaged $114.9 million across 5 years, with a median of $109.9 million in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 384.28% — and 2025, when it plunged 43.26%.
- Erasca's Non-Current Assets stood at $70.4 million in 2022, then advanced by 5.98% to $74.6 million in 2023, then soared by 159.62% to $193.7 million in 2024, then sank by 43.26% to $109.9 million in 2025, then jumped by 88.74% to $207.4 million in 2026.
- The last three Non-Current Assets figures came in at $207.4 million (Q1 2026), $109.9 million (Q4 2025), and $120.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | 207.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 207.45 Mn |
| Dec 31, 2025 | 109.92 Mn |
| Sep 30, 2025 | 120.48 Mn |
| Jun 30, 2025 | 134.73 Mn |
| Mar 31, 2025 | 156.63 Mn |
| Dec 31, 2024 | 193.73 Mn |
| Sep 30, 2024 | 198.72 Mn |
| Jun 30, 2024 | 107.74 Mn |
| Mar 31, 2024 | 63.40 Mn |
| Dec 31, 2023 | 74.62 Mn |
| Sep 30, 2023 | 113.44 Mn |
| Jun 30, 2023 | 116.81 Mn |
| Mar 31, 2023 | 69.66 Mn |
| Dec 31, 2022 | 70.41 Mn |
| Sep 30, 2022 | 80.68 Mn |
| Jun 30, 2022 | 63.40 Mn |
| Mar 31, 2022 | 72.10 Mn |
| Dec 31, 2021 | 81.40 Mn |
| Sep 30, 2021 | 29.64 Mn |
| Jun 30, 2021 | 13.09 Mn |